Insmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Insmed (INSM).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

21Buy

Consensus RatingBuy# Analysts21Avg. Consensus PT$196Upside to Avg. PT+80.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$205→$201
Oct 21, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$218→$213
Oct 12, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Oct 12, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$220
Sep 30, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$237→$207
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$188
Sep 15, 2026	Roth Capital	Adam Walsh	PT Cut	Buy	$212→$198
Aug 10, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$179→$175
Aug 10, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$185→$195
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$207→$205
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$161→$169
Aug 7, 2026	Evercore ISI Group	Josh Schimmer	PT Raise	Outperform	$160→$170
Jul 21, 2026	BMO Capital	Connor Mackay	Initiate	Outperform	$192
Jul 15, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$160→$161
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$207
Jun 22, 2026	Evercore ISI Group	Josh Schimmer	PT Cut	Outperform	$162→$160
Jun 8, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$180→$179
Jun 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$205→$195
May 14, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$205→$185
May 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$220→$205